We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » DRUG-ELUTING STENT MARKET COMPETITION HEATING UP
DRUG-ELUTING STENT MARKET COMPETITION HEATING UP
March 24, 2004
Boston Scientific is proving to be a fierce contender in the highly competitive coronary stent field. About two weeks after Boston Scientific launched its Taxus Express2 paclitaxel-eluting coronary stent system on March 4, the firm had rung up U.S. sales of about $42 million.